remdesivir in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03]
0.73 [0.52 ; 1.03 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable deathsdetailed results NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
0.55 [0.36 ; 0.84 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84]
0.55 [0.36 ; 0.84 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable clinical improvementdetailed results NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.29 [1.12 ; 1.49 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable clinical improvement (28-day)detailed results NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76]
1.35 [1.03 ; 1.76 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable clinical improvement (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49]
1.29 [1.12 ; 1.49 ] NIH NIAID ACTT-1, 2020 1 0% 1,062 NA not evaluable serious adverse eventsdetailed results NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96]
0.72 [0.54 ; 0.96 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable deep vein thrombosisdetailed results NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81]
0.64 [0.23 ; 1.81 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable elevated liver enzymesdetailed results NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18]
0.67 [0.38 ; 1.18 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable hyperbilirubinemiadetailed results NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34]
0.84 [0.30 ; 2.34 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable pulmonary embolismdetailed results NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80]
0.96 [0.19 ; 4.80 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable renal impairmentdetailed results NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61]
1.02 [0.64 ; 1.61 ] NIH NIAID ACTT-1, 2020 1 0% 1,063 NA not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:02 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 94
- treatments: 510
- roots T: 290